<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:16:46Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9175188" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9175188</identifier>
        <datestamp>2022-06-09</datestamp>
        <setSpec>ehjcvp</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Eur Heart J Cardiovasc Pharmacother</journal-id>
              <journal-id journal-id-type="iso-abbrev">Eur Heart J Cardiovasc Pharmacother</journal-id>
              <journal-id journal-id-type="publisher-id">ehjcvp</journal-id>
              <journal-title-group>
                <journal-title>European Heart Journal — Cardiovascular Pharmacotherapy</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">2055-6837</issn>
              <issn pub-type="epub">2055-6845</issn>
              <publisher>
                <publisher-name>Oxford University Press</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9175188</article-id>
              <article-id pub-id-type="pmcid">PMC9175188</article-id>
              <article-id pub-id-type="pmc-uid">9175188</article-id>
              <article-id pub-id-type="pmid">34958366</article-id>
              <article-id pub-id-type="pmid">34958366</article-id>
              <article-id pub-id-type="doi">10.1093/ehjcvp/pvab090</article-id>
              <article-id pub-id-type="publisher-id">pvab090</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Original Article</subject>
                </subj-group>
                <subj-group subj-group-type="category-taxonomy-collection">
                  <subject>AcademicSubjects/MED00200</subject>
                  <subject>AcademicSubjects/MED00410</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: a <italic toggle="yes">post hoc</italic> analysis of the ATHENA trial</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1611-4443</contrib-id>
                  <name>
                    <surname>Vamos</surname>
                    <given-names>Mate</given-names>
                  </name>
                  <!--vamos.mate@gmail.com-->
                  <aff><institution>Cardiac Electrophysiology Division, Department of Internal Medicine, University of Szeged</institution>, <addr-line>Szeged</addr-line>, <country country="HU">Hungary</country></aff>
                  <xref rid="cor1" ref-type="corresp"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9969-3921</contrib-id>
                  <name>
                    <surname>Oldgren</surname>
                    <given-names>Jonas</given-names>
                  </name>
                  <aff><institution>Uppsala Clinical Research Center and Department of Medical Sciences, Uppsala University</institution>, <addr-line>Uppsala</addr-line>, <country country="SE">Sweden</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Nam</surname>
                    <given-names>Gi-Byoung</given-names>
                  </name>
                  <aff><institution>Asan Medical Center, University of Ulsan College of Medicine</institution>, <addr-line>Seoul</addr-line>, <country country="KR">South Korea</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lip</surname>
                    <given-names>Gregory Y H</given-names>
                  </name>
                  <aff><institution>Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart &amp; Chest Hospital</institution>, <addr-line>Liverpool</addr-line>, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9262-9433</contrib-id>
                  <name>
                    <surname>Calkins</surname>
                    <given-names>Hugh</given-names>
                  </name>
                  <aff><institution>Division of Cardiology, Department of Medicine, Johns Hopkins University</institution>, <addr-line>Baltimore, MD</addr-line>, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4309-5789</contrib-id>
                  <name>
                    <surname>Zhu</surname>
                    <given-names>Jun</given-names>
                  </name>
                  <aff><institution>Fuwai Hospital, CAMS &amp; PUMC</institution>, <addr-line>Beijing</addr-line>, <country country="CN">China</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ueng</surname>
                    <given-names>Kwo-Chang</given-names>
                  </name>
                  <aff><institution>Division of Cardiology, Department of Internal Medicine, Chung-Shan Medical University Hospital</institution>, <addr-line>Taichung City</addr-line>, <country country="TW">Taiwan</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ludwigs</surname>
                    <given-names>Ulf</given-names>
                  </name>
                  <aff><institution>Sanofi</institution>, <addr-line>Stockholm</addr-line>, <country country="SE">Sweden</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wieloch</surname>
                    <given-names>Mattias</given-names>
                  </name>
                  <aff><institution>Sanofi</institution>, <addr-line>Paris</addr-line>, <country country="FR">France</country></aff>
                  <aff><institution>Department of Clinical Sciences Malmö, Lund University</institution>, <addr-line>Malmö</addr-line>, <country country="SE">Sweden</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Stewart</surname>
                    <given-names>John</given-names>
                  </name>
                  <aff><institution>Sanofi</institution>, <addr-line>Laval, Quebec</addr-line>, <country country="CA">Canada</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hohnloser</surname>
                    <given-names>Stefan H</given-names>
                  </name>
                  <aff><institution>Department of Cardiology, J.W. Goethe University</institution>, <addr-line>Frankfurt</addr-line>, <country country="DE">Germany</country></aff>
                </contrib>
              </contrib-group>
              <author-notes>
                <corresp id="cor1">Corresponding author. Tel: +36 62 341 559, Fax: +36 62 342 538, Email: <email>vamos.mate@gmail.com</email></corresp>
              </author-notes>
              <pub-date pub-type="collection">
                <month>7</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="epub" iso-8601-date="2021-12-27">
                <day>27</day>
                <month>12</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>27</day>
                <month>12</month>
                <year>2021</year>
              </pub-date>
              <volume>8</volume>
              <issue>4</issue>
              <fpage>363</fpage>
              <lpage>371</lpage>
              <history>
                <date date-type="received">
                  <day>23</day>
                  <month>8</month>
                  <year>2021</year>
                </date>
                <date date-type="rev-recd">
                  <day>03</day>
                  <month>12</month>
                  <year>2021</year>
                </date>
                <date date-type="rev-request">
                  <day>20</day>
                  <month>12</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>22</day>
                  <month>12</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.</copyright-statement>
                <copyright-year>2021</copyright-year>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact <email>journals.permissions@oup.com</email></license-p>
                </license>
              </permissions>
              <self-uri xlink:href="pvab090.pdf"/>
              <abstract>
                <title>Abstract</title>
                <sec id="abs1">
                  <title>Aims</title>
                  <p>Use of antiarrhythmic drugs (AADs) in patients with chronic kidney disease (CKD) is challenging owing to issues with renal clearance, drug accumulation, and increased proarrhythmic risks. Because CKD is a common comorbidity in patients with atrial fibrillation/atrial flutter (AF/AFL), it is important to establish the efficacy and safety of AAD treatment in patients with CKD.</p>
                </sec>
                <sec id="abs2">
                  <title>Methods and results</title>
                  <p>Dronedarone efficacy and safety in individuals with AF/AFL and varying renal functionality [estimated glomerular filtration rate (eGFR): ≥60, ≥45 and &lt;60, and &lt;45 mL/min] was investigated in a <italic toggle="yes">post hoc</italic> analysis of ATHENA (NCT00174785), a randomized, double-blind trial of dronedarone vs. placebo in patients with paroxysmal or persistent AF/AFL plus additional cardiovascular (CV) risk factors. Log-rank testing and Cox regression were used to compare the incidence of endpoints between treatments. Overall, 4588 participants were enrolled from the trial. There was no interaction between treatment group and baseline eGFR assessed as a continuous variable (<italic toggle="yes">P</italic> = 0.743) for the first CV hospitalization or death from any cause (primary outcome). This outcome was lower with dronedarone vs. placebo across a wide range of renal function. First CV hospitalization and first AF/AFL recurrence were both lower in the two least renally impaired subgroups with dronedarone vs. placebo. Treatment emergent adverse events leading to treatment discontinuation were more frequent with dronedarone vs. placebo and occurred more often in patients with severe renal impairment.</p>
                </sec>
                <sec id="abs3">
                  <title>Conclusion</title>
                  <p>Dronedarone is an effective AAD in patients with AF/AFL and CV risk factors across a wide range of renal function.</p>
                </sec>
              </abstract>
              <abstract abstract-type="graphical">
                <title>Graphical Abstract</title>
                <p>
                  <fig position="float" id="ga1">
                    <label>Graphical Abstract</label>
                    <caption>
                      <p>Post-hoc analysis of the ATHENA trial demonstrates the efficacy of dronedarone across a wide range of renal function</p>
                    </caption>
                    <graphic xlink:href="pvab090fig1g" position="float"/>
                  </fig>
                </p>
              </abstract>
              <kwd-group kwd-group-type="keywords">
                <kwd>Dronedarone</kwd>
                <kwd>Atrial fibrillation</kwd>
                <kwd>Atrial flutter</kwd>
                <kwd>Chronic kidney disease</kwd>
                <kwd>ATHENA</kwd>
                <kwd>Safety</kwd>
              </kwd-group>
              <funding-group>
                <award-group award-type="grant">
                  <funding-source>
                    <institution-wrap>
                      <institution>Sanofi</institution>
                      <institution-id institution-id-type="DOI">10.13039/100004339</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
              </funding-group>
              <counts>
                <page-count count="9"/>
              </counts>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro" id="sec1">
              <title>Introduction</title>
              <p>Atrial fibrillation (AF) and atrial flutter (AFL) are the most frequently encountered arrhythmias. AF-related symptoms and the risk of strokes are significantly improved with ventricular rate control and anticoagulation; controlling sinus rhythm can improve exercise capacity and quality of life in patients with AF.<sup><xref rid="bib1" ref-type="bibr">1</xref>,<xref rid="bib2" ref-type="bibr">2</xref></sup> As demonstrated in the recent EAST-AFNET 4 trial, early comprehensive rhythm control [such as antiarrhythmic drugs (AADs)] as part of a structured holistic management pathway is associated with a lower risk of cardiovascular (CV) outcomes in patients with newly diagnosed AF.<sup><xref rid="bib3" ref-type="bibr">3</xref></sup></p>
              <p>AF/AFL is estimated to occur in 15–40% of patients with chronic kidney disease (CKD).<sup><xref rid="bib4" ref-type="bibr">4</xref></sup> Additionally, mild CKD and moderate-to-severe CKD have been found to be independent risk factors for all-cause mortality in patients with AF/AFL.<sup><xref rid="bib5" ref-type="bibr">5</xref></sup> However, the use of AADs in patients with CKD is challenging because of the increased proarrhythmic risks, especially in patients with CKD and concomitant structural heart disease.<sup><xref rid="bib4" ref-type="bibr">4</xref></sup> A further concern is that administration of drugs that rely on kidney elimination can result in accumulation and drug toxicity,<sup><xref rid="bib6" ref-type="bibr">6</xref></sup> especially as renal function deteriorates over time. Because CKD and AF are often coexisting<sup><xref rid="bib7" ref-type="bibr">7</xref></sup> and increase with an advancing age, it is important to establish the efficacy and safety for AAD treatment in patients with AF and CKD. A <italic toggle="yes">post hoc</italic> analysis of the BALKAN-AF survey found that AF patients with CKD received less rhythm control than rate control; when they did receive rhythm control, it was almost exclusively amiodarone,<sup><xref rid="bib8" ref-type="bibr">8</xref></sup> speaking to the need for increased awareness of the safety and efficacy of available alternative rhythm control therapies.</p>
              <p>ATHENA (A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg bid for the Prevention of Cardiovascular Hospitalization or Death from Any Cause in Patients with Atrial Fibrillation/Atrial Flutter; NCT00174785) was a randomized, double-blind, placebo-controlled trial to evaluate the use of dronedarone in patients with AF/AFL who had additional risk factors for death.<sup><xref rid="bib9" ref-type="bibr">9</xref></sup> The study found that dronedarone reduced the incidence of CV hospitalization or death in patients with paroxysmal or persistent AF/AFL.<sup><xref rid="bib9" ref-type="bibr">9</xref></sup></p>
              <p>The aim of this <italic toggle="yes">post hoc</italic> analysis of the ATHENA trial was to evaluate the impact of dronedarone on CV hospitalization or death from any cause and safety outcomes in patients enrolled in the trial across a range of renal function.</p>
            </sec>
            <sec sec-type="materials|methods" id="sec2">
              <title>Methods</title>
              <sec id="sec2-1">
                <title>Study design</title>
                <p>Details of the ATHENA trial have been described previously.<sup><xref rid="bib9" ref-type="bibr">9</xref>,<xref rid="bib10" ref-type="bibr">10</xref></sup> Briefly, ATHENA was a randomized, placebo-controlled, multicentre, double-blind, parallel-group trial that assessed the efficacy of dronedarone for the prevention of CV hospitalization or death from any cause in patients ≥70 years of age with paroxysmal or persistent AF/AFL and additional CV risk factors (arterial hypertension, previous stroke, transient ischaemic attack or systemic embolism, diabetes mellitus, left atrial diameter ≥50 mm, or left ventricular ejection fraction ≤40%). Patients with an estimated glomerular filtration rate (eGFR) of ≥10 mL/min (Cockcroft–Gault) were included in the study. Detailed patient eligibility and exclusion criteria can be found in the <xref rid="sup1" ref-type="supplementary-material">Supplementary material online</xref>. The study protocol was approved by the institutional review board at each participating institution.</p>
              </sec>
              <sec id="sec2-2">
                <title>Randomization and follow-up</title>
                <p>Eligible patients were randomly assigned to either oral dronedarone 400 mg twice daily or a matching placebo (1:1 ratio). Assessment of vital signs and electrocardiography (ECG) were performed on Days 7 and 14 and at 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, and 30 months. Renal function was assessed by clearance of serum creatinine at each follow-up visit.</p>
              </sec>
              <sec id="sec2-3">
                <title>Study endpoints</title>
                <p>The primary outcome of the ATHENA study<sup><xref rid="bib9" ref-type="bibr">9</xref>,<xref rid="bib10" ref-type="bibr">10</xref></sup> and this exploratory <italic toggle="yes">post hoc</italic> analysis was first CV hospitalization or death from any cause. Secondary endpoints were as follows: death from any cause, death from CV causes, first hospitalization due to CV events, and first documented recurrence of AF/AFL (assessed using standard ECG at follow-up visits). Safety outcomes including treatment-emergent adverse events (TEAEs), defined as an adverse event occurring between first dose of the study drug and 10 days after the last dose, and TEAE leading to discontinuation were also evaluated.</p>
              </sec>
              <sec id="sec2-4">
                <title>Statistical analysis</title>
                <p>The original analysis of the ATHENA study used the Cockcroft–Gault formula.<sup><xref rid="bib10" ref-type="bibr">10</xref></sup> In this exploratory subanalysis, renal function (eGFR) was assessed using the CKD-Epidemiology Collaboration (CKD-EPI) equation.<sup><xref rid="bib11" ref-type="bibr">11</xref></sup> Patients were then grouped by eGFR strata in the following subgroups: ≥60, ≥45 and &lt;60, and &lt;45 mL/min. For confirmation purposes, outcomes were also analysed in eGFR strata classified according to the Modification of Diet in Renal Disease (MDRD) Study Group criteria and the Cockcroft–Gault formula.</p>
                <p>Log-rank testing and Cox regression were used to compare time to events between treatment groups. Modelling was performed of time-to-event according to treatment, baseline CKD (eGFR assessed as a continuous variable), and its interaction, using restricted cubic spline for CKD. The restricted cubic spline analysis enabled the model to fit the non-linearity of the CKD effect by the addition of <italic toggle="yes">k</italic>-2 covariates of degree 3, with <italic toggle="yes">k</italic> being the number of knots. A Cox model with interaction was used to analyse time-to-event adjusted for treatment, CKD (CKD itself + three cubic terms = four covariates), and the four treatment-by-CKD interaction terms using SAS Proc PHREG.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="sec3">
              <title>Results</title>
              <sec id="sec3-1">
                <title>Baseline characteristics</title>
                <p>The analysis included data from 4588 participants of the 4628 recruited for the ATHENA trial (<italic toggle="yes">Table</italic> <xref rid="tbl1" ref-type="table"><italic toggle="yes">1</italic></xref>). In total, 57% of patients had either no decrease or a mild decrease in eGFR (≥60 mL/min subgroup), 29% had a mild-to-moderate decrease in eGFR (≥45 and &lt;60 mL/min subgroup), and the remaining 14% presented with moderate-to-severe decreases in eGFR (&lt;45 mL/min subgroup). Median baseline eGFR for placebo and dronedarone were 74.1 and 73.2 mL/min, respectively, in the ≥60 mL/min subgroup, 53.4 and 53.5 mL/min, respectively, in the ≥45 and &lt;60 mL/min subgroup, and 37.9 and 39.5 mL/min, respectively, in the &lt;45 mL/min subgroup. The proportion of males in the subgroups decreased with worsening renal function. There was a trend towards increasing mean age and greater proportions with structural heart disease and coronary heart disease as renal function worsened. Mean CHA<sub>2</sub>DS<sub>2</sub>-VASc scores (congestive heart failure, hypertension, age ≥75 [doubled], diabetes, stroke [doubled], vascular disease, age 65 to 74, sex category [female]) also increased with decreasing renal function. In the ≥60 mL/min subgroup, ∼50% of participants had CHA<sub>2</sub>DS<sub>2</sub>-VASc scores &gt;2, compared with ∼85% in the &lt;45 mL/min subgroup.</p>
                <table-wrap position="float" id="tbl1">
                  <label>Table 1</label>
                  <caption>
                    <p>Demographic characteristics, cardiovascular disease history, and cardiovascular disease medication use</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <thead>
                      <tr>
                        <th rowspan="1" colspan="1"/>
                        <th align="center" colspan="2" rowspan="1">eGFR ≥60 mL/min</th>
                        <th align="center" colspan="2" rowspan="1">eGFR ≥45 and &lt;60 mL/min</th>
                        <th align="center" colspan="2" rowspan="1">eGFR &lt;45 mL/min</th>
                      </tr>
                      <tr>
                        <th align="left" rowspan="1" colspan="1">Characteristic, <italic toggle="yes">n</italic> (%)<sup><xref rid="tb1fn1" ref-type="table-fn">a</xref></sup></th>
                        <th align="left" rowspan="1" colspan="1">Placebo (<italic toggle="yes">n</italic> = 1301)</th>
                        <th align="left" rowspan="1" colspan="1">Dronedarone (<italic toggle="yes">n</italic> = 1320)</th>
                        <th align="left" rowspan="1" colspan="1">Placebo (<italic toggle="yes">n</italic> = 683)</th>
                        <th align="left" rowspan="1" colspan="1">Dronedarone (<italic toggle="yes">n</italic> = 649)</th>
                        <th align="left" rowspan="1" colspan="1">Placebo (<italic toggle="yes">n</italic> = 322)</th>
                        <th align="left" rowspan="1" colspan="1">Dronedarone (<italic toggle="yes">n</italic> = 313)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td rowspan="1" colspan="1">Age (years), mean ± SD</td>
                        <td rowspan="1" colspan="1">69.0 ± 9.4</td>
                        <td rowspan="1" colspan="1">69.2 ± 9.5</td>
                        <td rowspan="1" colspan="1">74.5 ± 7.2</td>
                        <td rowspan="1" colspan="1">73.6 ± 6.9</td>
                        <td rowspan="1" colspan="1">76.7 ± 6.6</td>
                        <td rowspan="1" colspan="1">77.1 ± 6.3</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Sex, male</td>
                        <td rowspan="1" colspan="1">819 (63.0)</td>
                        <td rowspan="1" colspan="1">745 (56.4)</td>
                        <td rowspan="1" colspan="1">327 (47.9)</td>
                        <td rowspan="1" colspan="1">300 (46.2)</td>
                        <td rowspan="1" colspan="1">131 (40.7)</td>
                        <td rowspan="1" colspan="1">114 (36.4)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">BMI ≥30 kg/m<sup>2</sup></td>
                        <td rowspan="1" colspan="1">435 (33.4)</td>
                        <td rowspan="1" colspan="1">410 (31.1)</td>
                        <td rowspan="1" colspan="1">193 (28.3)</td>
                        <td rowspan="1" colspan="1">222 (34.2)</td>
                        <td rowspan="1" colspan="1">99 (30.7)</td>
                        <td rowspan="1" colspan="1">119 (38.0)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">eGFR (mL/min) at baseline, median (Q1, Q3)</td>
                        <td rowspan="1" colspan="1">74.1 (66.5, 84.7)</td>
                        <td rowspan="1" colspan="1">73.2 (66.5, 84.1)</td>
                        <td rowspan="1" colspan="1">53.4 (49.3, 56.6)</td>
                        <td rowspan="1" colspan="1">53.5 (49.9, 56.6)</td>
                        <td rowspan="1" colspan="1">37.9 (33.5, 42.0)</td>
                        <td rowspan="1" colspan="1">39.5 (33.7, 42.6)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Creatinine (μmol/L) at baseline, median (Q1, Q3)</td>
                        <td rowspan="1" colspan="1">80.0 (70.7, 94.0)</td>
                        <td rowspan="1" colspan="1">79.6 (70.7, 90.0)</td>
                        <td rowspan="1" colspan="1">104.0 (91.0, 114.9)</td>
                        <td rowspan="1" colspan="1">103.0 (92.0, 114.9)</td>
                        <td rowspan="1" colspan="1">132.6 (117.0, 150.3)</td>
                        <td rowspan="1" colspan="1">132.6 (114.9, 150.3)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Hypertension</td>
                        <td rowspan="1" colspan="1">1113 (85.5)</td>
                        <td rowspan="1" colspan="1">1124 (85.2)</td>
                        <td rowspan="1" colspan="1">585 (85.7)</td>
                        <td rowspan="1" colspan="1">575 (88.6)</td>
                        <td rowspan="1" colspan="1">280 (87.0)</td>
                        <td rowspan="1" colspan="1">285 (91.1)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Structural heart disease</td>
                        <td rowspan="1" colspan="1">723 (56.1)</td>
                        <td rowspan="1" colspan="1">708 (54.2)</td>
                        <td rowspan="1" colspan="1">438 (64.2)</td>
                        <td rowspan="1" colspan="1">391 (60.4)</td>
                        <td rowspan="1" colspan="1">233 (72.6)</td>
                        <td rowspan="1" colspan="1">221 (70.6)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Coronary heart disease</td>
                        <td rowspan="1" colspan="1">350 (26.9)</td>
                        <td rowspan="1" colspan="1">345 (26.1)</td>
                        <td rowspan="1" colspan="1">240 (35.1)</td>
                        <td rowspan="1" colspan="1">194 (29.9)</td>
                        <td rowspan="1" colspan="1">133 (41.3)</td>
                        <td rowspan="1" colspan="1">117 (37.4)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Any CHF</td>
                        <td rowspan="1" colspan="1">328 (25.2)</td>
                        <td rowspan="1" colspan="1">326 (24.7)</td>
                        <td rowspan="1" colspan="1">227 (33.2)</td>
                        <td rowspan="1" colspan="1">215 (33.1)</td>
                        <td rowspan="1" colspan="1">135 (41.9)</td>
                        <td rowspan="1" colspan="1">127 (40.6)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Ischaemic dilated cardiomyopathy</td>
                        <td rowspan="1" colspan="1">49 (3.8)</td>
                        <td rowspan="1" colspan="1">38 (2.9)</td>
                        <td rowspan="1" colspan="1">39 (5.7)</td>
                        <td rowspan="1" colspan="1">23 (3.5)</td>
                        <td rowspan="1" colspan="1">29 (9.0)</td>
                        <td rowspan="1" colspan="1">30 (9.6)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Non-ischaemic dilated cardiomyopathy</td>
                        <td rowspan="1" colspan="1">51 (3.9)</td>
                        <td rowspan="1" colspan="1">50 (3.8)</td>
                        <td rowspan="1" colspan="1">22 (3.2)</td>
                        <td rowspan="1" colspan="1">19 (2.9)</td>
                        <td rowspan="1" colspan="1">11 (3.4)</td>
                        <td rowspan="1" colspan="1">11 (3.5)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Rheumatic valvular heart disease</td>
                        <td rowspan="1" colspan="1">13 (1.0)</td>
                        <td rowspan="1" colspan="1">30 (2.3)</td>
                        <td rowspan="1" colspan="1">7 (1.0)</td>
                        <td rowspan="1" colspan="1">14 (2.2)</td>
                        <td rowspan="1" colspan="1">9 (2.8)</td>
                        <td rowspan="1" colspan="1">7 (2.2)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Non-rheumatic valvular heart disease</td>
                        <td rowspan="1" colspan="1">169 (13.0)</td>
                        <td rowspan="1" colspan="1">164 (12.4)</td>
                        <td rowspan="1" colspan="1">127 (18.6)</td>
                        <td rowspan="1" colspan="1">105 (16.2)</td>
                        <td rowspan="1" colspan="1">55 (17.1)</td>
                        <td rowspan="1" colspan="1">60 (19.2)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Hypertrophic cardiomyopathy</td>
                        <td rowspan="1" colspan="1">28 (2.2)</td>
                        <td rowspan="1" colspan="1">23 (1.7)</td>
                        <td rowspan="1" colspan="1">14 (2.0)</td>
                        <td rowspan="1" colspan="1">10 (1.5)</td>
                        <td rowspan="1" colspan="1">7 (2.2)</td>
                        <td rowspan="1" colspan="1">12 (3.8)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Congenital heart disease</td>
                        <td rowspan="1" colspan="1">9 (0.7)</td>
                        <td rowspan="1" colspan="1">14 (1.1)</td>
                        <td rowspan="1" colspan="1">4 (0.6)</td>
                        <td rowspan="1" colspan="1">3 (0.5)</td>
                        <td rowspan="1" colspan="1">3 (0.9)</td>
                        <td rowspan="1" colspan="1">4 (1.3)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">CHA<sub>2</sub>DS<sub>2</sub>-VASc score, mean ± SD</td>
                        <td rowspan="1" colspan="1">2.5 ± 1.1</td>
                        <td rowspan="1" colspan="1">2.6 ± 1.1</td>
                        <td rowspan="1" colspan="1">3.1 ± 1.0</td>
                        <td rowspan="1" colspan="1">3.1 ± 1.0</td>
                        <td rowspan="1" colspan="1">3.5 ± 1.0</td>
                        <td rowspan="1" colspan="1">3.6 ± 1.0</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">CHA<sub>2</sub>DS<sub>2</sub>-VASc &lt;2</td>
                        <td rowspan="1" colspan="1">228 (19.1)</td>
                        <td rowspan="1" colspan="1">224 (17.0)</td>
                        <td rowspan="1" colspan="1">43 (6.3)</td>
                        <td rowspan="1" colspan="1">32 (4.9)</td>
                        <td rowspan="1" colspan="1">8 (2.5)</td>
                        <td rowspan="1" colspan="1">7 (2.2)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">CHA<sub>2</sub>DS<sub>2</sub>-VASc: 2</td>
                        <td rowspan="1" colspan="1">429 (33.0)</td>
                        <td rowspan="1" colspan="1">395 (29.9)</td>
                        <td rowspan="1" colspan="1">134 (19.6)</td>
                        <td rowspan="1" colspan="1">140 (21.6)</td>
                        <td rowspan="1" colspan="1">42 (13.0)</td>
                        <td rowspan="1" colspan="1">36 (11.5)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">CHA<sub>2</sub>DS<sub>2</sub>-VASc &gt;2</td>
                        <td rowspan="1" colspan="1">624 (48.0)</td>
                        <td rowspan="1" colspan="1">701 (53.1)</td>
                        <td rowspan="1" colspan="1">506 (74.1)</td>
                        <td rowspan="1" colspan="1">477 (73.5)</td>
                        <td rowspan="1" colspan="1">272 (84.5)</td>
                        <td rowspan="1" colspan="1">270 (86.3)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">NYHA class</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Class 1</td>
                        <td rowspan="1" colspan="1">103 (7.9)</td>
                        <td rowspan="1" colspan="1">137 (10.4)</td>
                        <td rowspan="1" colspan="1">47 (6.9)</td>
                        <td rowspan="1" colspan="1">49 (7.6)</td>
                        <td rowspan="1" colspan="1">27 (8.4)</td>
                        <td rowspan="1" colspan="1">22 (7.0)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Class 2</td>
                        <td rowspan="1" colspan="1">186 (14.3)</td>
                        <td rowspan="1" colspan="1">155 (11.7)</td>
                        <td rowspan="1" colspan="1">136 (19.9)</td>
                        <td rowspan="1" colspan="1">134 (20.6)</td>
                        <td rowspan="1" colspan="1">82 (25.5)</td>
                        <td rowspan="1" colspan="1">81 (25.9)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Class 3</td>
                        <td rowspan="1" colspan="1">39 (3.0)</td>
                        <td rowspan="1" colspan="1">34 (2.6)</td>
                        <td rowspan="1" colspan="1">44 (6.4)</td>
                        <td rowspan="1" colspan="1">32 (4.9)</td>
                        <td rowspan="1" colspan="1">26 (8.1)</td>
                        <td rowspan="1" colspan="1">24 (7.7)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Left ventricular ejection fraction, mean ± SD</td>
                        <td rowspan="1" colspan="1">57.58 (10.50)</td>
                        <td rowspan="1" colspan="1">58.07 (10.36)</td>
                        <td rowspan="1" colspan="1">57.46 (11.74)</td>
                        <td rowspan="1" colspan="1">56.92 (11.23)</td>
                        <td rowspan="1" colspan="1">55.88 (12.81)</td>
                        <td rowspan="1" colspan="1">55.19 (12.48)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Pacemaker</td>
                        <td rowspan="1" colspan="1">98 (7.5)</td>
                        <td rowspan="1" colspan="1">91 (6.9)</td>
                        <td rowspan="1" colspan="1">96 (14.1)</td>
                        <td rowspan="1" colspan="1">66 (10.2)</td>
                        <td rowspan="1" colspan="1">46 (14.3)</td>
                        <td rowspan="1" colspan="1">54 (17.3)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Implanted cardioverter defibrillator</td>
                        <td rowspan="1" colspan="1">18 (1.4)</td>
                        <td rowspan="1" colspan="1">12 (0.9)</td>
                        <td rowspan="1" colspan="1">13 (1.9)</td>
                        <td rowspan="1" colspan="1">12 (1.8)</td>
                        <td rowspan="1" colspan="1">11 (3.4)</td>
                        <td rowspan="1" colspan="1">18 (5.8)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Left atrial diameter (mm), mean ± SD</td>
                        <td rowspan="1" colspan="1">43.91 (6.91)</td>
                        <td rowspan="1" colspan="1">43.90 (6.73)</td>
                        <td rowspan="1" colspan="1">43.91 (6.97)</td>
                        <td rowspan="1" colspan="1">44.11 (6.57)</td>
                        <td rowspan="1" colspan="1">44.72 (7.72)</td>
                        <td rowspan="1" colspan="1">44.69 (7.34)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">CVD medication use</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Beta blockers (except sotalol)</td>
                        <td rowspan="1" colspan="1">921 (70.8)</td>
                        <td rowspan="1" colspan="1">919 (69.6)</td>
                        <td rowspan="1" colspan="1">476 (69.7)</td>
                        <td rowspan="1" colspan="1">483 (74.4)</td>
                        <td rowspan="1" colspan="1">237 (73.6)</td>
                        <td rowspan="1" colspan="1">219 (70.0)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">ACE or AII inhibitor</td>
                        <td rowspan="1" colspan="1">886 (68.1)</td>
                        <td rowspan="1" colspan="1">906 (68.6)</td>
                        <td rowspan="1" colspan="1">484 (70.9)</td>
                        <td rowspan="1" colspan="1">478 (73.7)</td>
                        <td rowspan="1" colspan="1">226 (70.2)</td>
                        <td rowspan="1" colspan="1">226 (72.2)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Calcium channel blocker (rate lowering)</td>
                        <td rowspan="1" colspan="1">173 (13.3)</td>
                        <td rowspan="1" colspan="1">195 (14.8)</td>
                        <td rowspan="1" colspan="1">97 (14.2)</td>
                        <td rowspan="1" colspan="1">89 (13.7)</td>
                        <td rowspan="1" colspan="1">36 (11.2)</td>
                        <td rowspan="1" colspan="1">47 (15.0)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Diuretics other than spironolactone</td>
                        <td rowspan="1" colspan="1">622 (47.8)</td>
                        <td rowspan="1" colspan="1">619 (46.9)</td>
                        <td rowspan="1" colspan="1">382 (55.9)</td>
                        <td rowspan="1" colspan="1">366 (56.4)</td>
                        <td rowspan="1" colspan="1">217 (67.4)</td>
                        <td rowspan="1" colspan="1">198 (63.3)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Spironolactone</td>
                        <td rowspan="1" colspan="1">63 (4.8)</td>
                        <td rowspan="1" colspan="1">64 (4.8)</td>
                        <td rowspan="1" colspan="1">33 (4.8)</td>
                        <td rowspan="1" colspan="1">48 (7.4)</td>
                        <td rowspan="1" colspan="1">39 (12.1)</td>
                        <td rowspan="1" colspan="1">35 (11.2)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Vitamin K antagonists</td>
                        <td rowspan="1" colspan="1">812 (62.4)</td>
                        <td rowspan="1" colspan="1">827 (62.7)</td>
                        <td rowspan="1" colspan="1">381 (55.8)</td>
                        <td rowspan="1" colspan="1">376 (57.9)</td>
                        <td rowspan="1" colspan="1">184 (57.1)</td>
                        <td rowspan="1" colspan="1">196 (62.6)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Low-dose aspirin (≤365 mg)</td>
                        <td rowspan="1" colspan="1">535 (41.1)</td>
                        <td rowspan="1" colspan="1">568 (43.0)</td>
                        <td rowspan="1" colspan="1">322 (47.1)</td>
                        <td rowspan="1" colspan="1">310 (47.8)</td>
                        <td rowspan="1" colspan="1">162 (50.3)</td>
                        <td rowspan="1" colspan="1">137 (43.8)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Other chronic antiplatelet therapy</td>
                        <td rowspan="1" colspan="1">77 (5.9)</td>
                        <td rowspan="1" colspan="1">74 (5.6)</td>
                        <td rowspan="1" colspan="1">52 (7.6)</td>
                        <td rowspan="1" colspan="1">35 (5.4)</td>
                        <td rowspan="1" colspan="1">37 (11.5)</td>
                        <td rowspan="1" colspan="1">17 (5.4)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Statins (CYP3A4 metabolized)</td>
                        <td rowspan="1" colspan="1">400 (30.7)</td>
                        <td rowspan="1" colspan="1">407 (30.8)</td>
                        <td rowspan="1" colspan="1">224 (32.8)</td>
                        <td rowspan="1" colspan="1">216 (33.3)</td>
                        <td rowspan="1" colspan="1">129 (40.1)</td>
                        <td rowspan="1" colspan="1">111 (35.5)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Statins (not CYP3A4 metabolized)</td>
                        <td rowspan="1" colspan="1">103 (7.9)</td>
                        <td rowspan="1" colspan="1">83 (6.3)</td>
                        <td rowspan="1" colspan="1">39 (5.7)</td>
                        <td rowspan="1" colspan="1">41 (6.3)</td>
                        <td rowspan="1" colspan="1">24 (7.5)</td>
                        <td rowspan="1" colspan="1">22 (7.0)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Moderate inhibitors of CYP3A4</td>
                        <td rowspan="1" colspan="1">122 (9.4)</td>
                        <td rowspan="1" colspan="1">136 (10.3)</td>
                        <td rowspan="1" colspan="1">74 (10.8)</td>
                        <td rowspan="1" colspan="1">56 (8.6)</td>
                        <td rowspan="1" colspan="1">30 (9.3)</td>
                        <td rowspan="1" colspan="1">22 (7.0)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Digoxin</td>
                        <td rowspan="1" colspan="1">179 (13.8)</td>
                        <td rowspan="1" colspan="1">188 (14.2)</td>
                        <td rowspan="1" colspan="1">84 (12.3)</td>
                        <td rowspan="1" colspan="1">88 (13.6)</td>
                        <td rowspan="1" colspan="1">45 (14.0)</td>
                        <td rowspan="1" colspan="1">43 (13.7)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Drugs interacting with creatinine renal tubular secretion<sup><xref rid="tb1fn2" ref-type="table-fn">b</xref></sup></td>
                        <td rowspan="1" colspan="1">124 (9.5)</td>
                        <td rowspan="1" colspan="1">125 (9.5)</td>
                        <td rowspan="1" colspan="1">69 (10.1)</td>
                        <td rowspan="1" colspan="1">75 (11.6)</td>
                        <td rowspan="1" colspan="1">43 (13.4)</td>
                        <td rowspan="1" colspan="1">28 (8.9)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">NSAID</td>
                        <td rowspan="1" colspan="1">60 (4.6)</td>
                        <td rowspan="1" colspan="1">69 (5.2)</td>
                        <td rowspan="1" colspan="1">34 (5.0)</td>
                        <td rowspan="1" colspan="1">31 (4.8)</td>
                        <td rowspan="1" colspan="1">29 (9.0)</td>
                        <td rowspan="1" colspan="1">14 (4.5)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="tb1fn1">
                      <label>a</label>
                      <p>Data are <italic toggle="yes">n</italic> (%) unless otherwise stated.</p>
                    </fn>
                    <fn id="tb1fn2">
                      <label>b</label>
                      <p>Presence of drugs that compete with creatinine for renal tubular secretion may result in reduced estimated glomerular filtration rate values, despite no change in renal functionality measured by other parameters.</p>
                    </fn>
                    <fn id="tb1fn3">
                      <p>ACE, angiotensin converting enzyme; AII, angiotensin II; BMI, body mass index; CHA<sub>2</sub>DS<sub>2</sub>-VASc, congestive heart failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled), vascular disease, age 65 to 74, sex category (female); CHF, chronic heart failure; CVD, cardiovascular disease; CYP3A4, cytochrome P450 3A4; eGFR, estimated glomerular filtration rate; NSAID, non-steroidal anti-inflammatory drug; Q1, quartile 1; Q3, quartile 3; and SD, standard deviation. Placebo group: <italic toggle="yes">n</italic> = 2306; dronedarone group: <italic toggle="yes">n</italic> = 2282.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="sec3-2">
                <title>Primary outcome: first cardiovascular hospitalization or death from any cause</title>
                <p>In an analysis of all patients, rates of first CV hospitalization or death were 857/2621 (32.7%) patients in the ≥60 mL/min subgroup, 496/1332 (37.2%) in the ≥45 and &lt;60 mL/min subgroup, and 279/635 (43.9%) in the &lt;45 mL/min subgroup. The effect of treatment with dronedarone vs. placebo on first CV hospitalization or death from any cause vs. baseline eGFR assessed as a continuous variable is depicted in <italic toggle="yes">Figure</italic> <xref rid="fig1" ref-type="fig"><italic toggle="yes">1</italic></xref>, showing a relatively consistent hazard ratio (HR) for the effect of dronedarone vs. placebo across a wide range of renal function, with no significant interaction between the study treatment group and CKD (<italic toggle="yes">P</italic> = 0.743). The number of patients experiencing first CV hospitalization or death from any cause was also analysed according to assigned renal function group (eGFR) (<italic toggle="yes">Figure</italic> <xref rid="fig2" ref-type="fig"><italic toggle="yes">2</italic></xref>). Fewer patients experienced first CV hospitalization or death from any cause in the dronedarone vs. placebo groups, showing an HR ranging from 0.73 [95% confidence interval (CI) 0.64–0.84] to 0.82 (95% CI 0.65–1.03) across the renal function groups, with no interaction effect of treatment group and CKD subgroup (<italic toggle="yes">P</italic> = 0.727). In a subanalysis of patients with severe renal impairment, similar results were observed [HR 0.77 (0.43–1.39) for eGFR ≥10 and &lt;30 mL/min; HR 0.83 (0.64–1.08) for eGFR ≥30 and &lt;45 mL/min; <xref rid="sup1" ref-type="supplementary-material">Supplementary material online, <italic toggle="yes">Figure S1</italic></xref>].</p>
                <fig position="float" id="fig1">
                  <label>Figure 1</label>
                  <caption>
                    <p>Hazard ratio (95% confidence interval) for first cardiovascular hospitalization or death from any cause related to treatment with dronedarone vs. placebo according to baseline estimated glomerular filtration rate. Hazard ratio and 95% confidence interval (dotted lines) shown. Test of interaction between treatment group and estimated glomerular filtration rate (Chronic Kidney Disease-Epidemiology Collaboration) as a continuous variable: <italic toggle="yes">P</italic>-value = 0.7434. CI, confidence interval; eGFR, estimated glomerular filtration rate; and HR, hazard ratio.</p>
                  </caption>
                  <graphic xlink:href="pvab090fig1" position="float"/>
                </fig>
                <fig position="float" id="fig2">
                  <label>Figure 2</label>
                  <caption>
                    <p>Number of patients experiencing first cardiovascular hospitalization or death from any cause. The ‘ATHENA primary analysis’ data are from Hohnloser <italic toggle="yes">et al</italic>.<sup><xref rid="bib9" ref-type="bibr">9</xref></sup>*Probability of interaction between the treatment group and the subgroup. Total patients in dronedarone and placebo subgroups—≥60 mL/min: 1320 and 1301; ≥45 and &lt;60 mL/min: 649 and 683; &lt;45 mL/min: 313 and 322. CKD-EPI, Chronic Kidney Disease-Epidemiology Collaboration; CI, confidence interval; CV, cardiovascular; eGFR, estimated glomerular filtration rate; HR, hazard ratio; and PBO, placebo.</p>
                  </caption>
                  <graphic xlink:href="pvab090fig2" position="float"/>
                </fig>
                <p>The number of patients who experienced a first CV hospitalization was lower with dronedarone compared with placebo, with an HR of 0.72 to 0.84 (<italic toggle="yes">P</italic> &lt; 0.01 in the ≥60 mL/min and ≥45 and &lt;60 mL/min groups; <italic toggle="yes">P</italic> &gt; 0.05 in the &lt;45 mL/min group) (<italic toggle="yes">Figure</italic> <xref rid="fig3" ref-type="fig"><italic toggle="yes">3</italic></xref><italic toggle="yes">A</italic>). There was no interaction effect of treatment group and CKD subgroup (<italic toggle="yes">P</italic> = 0.573). The number of patients who experienced death from any cause was numerically lower with dronedarone compared with placebo in the ≥60 and &lt;45 mL/min subgroups, and similar in the ≥45 and &lt;60 mL/min subgroup (<italic toggle="yes">Figure</italic> <xref rid="fig3" ref-type="fig"><italic toggle="yes">3</italic></xref><italic toggle="yes">B</italic>). However, log-rank test <italic toggle="yes">P</italic>-values were all &gt;0.05, likely due to the smaller patient populations following stratification. There was no interaction effect of treatment group and CKD subgroup (<italic toggle="yes">P</italic> = 0.576).</p>
                <fig position="float" id="fig3">
                  <label>Figure 3</label>
                  <caption>
                    <p>Number of patients with (<italic toggle="yes">A</italic>) first cardiovascular hospitalization, (<italic toggle="yes">B</italic>) death from any cause, and (<italic toggle="yes">C</italic>) first atrial fibrillation / atrial flutter recurrence. The ‘ATHENA primary analysis’ data are from Hohnloser <italic toggle="yes">et al</italic>.<sup><xref rid="bib9" ref-type="bibr">9</xref></sup> *Probability of interaction between the treatment group and the subgroup. Total patients in dronedarone and placebo subgroups—≥60 mL/min: 1320 and 1301; ≥45 and &lt;60 mL/min: 649 and 683; &lt;45 mL/min: 313 and 322. AF, atrial fibrillation; AFL, atrial flutter; CKD-EPI, Chronic Kidney Disease-Epidemiology Collaboration; CI, confidence interval; CV, cardiovascular; eGFR, estimated glomerular filtration rate; HR, hazard ratio; and PBO, placebo.</p>
                  </caption>
                  <graphic xlink:href="pvab090fig3" position="float"/>
                </fig>
              </sec>
              <sec id="sec3-3">
                <title>First recurrence of atrial fibrillation/atrial flutter</title>
                <p>Median time (in days) from randomization until first documented recurrence of AF/AFL was longer with dronedarone vs. placebo in all three subgroups [≥60 mL/min, 533 (386–552) vs. 197 (178–312); ≥45 and &lt;60 mL/min, 534 (378–593) vs. 187 (153–290); and &lt;45 mL/min, 363 (95% CI 191–555) vs. 183 (89–305)]. There was also a difference in the number of patients experiencing first recurrence of AF/AFL between the dronedarone and placebo groups favouring dronedarone (HR 0.78 and 0.76, <italic toggle="yes">P</italic> &lt; 0.01 for both, for the ≥60 mL/min and ≥45 and &lt;60 mL/min subgroups, respectively). The &lt;45 mL/min subgroup showed an HR of 0.85, <italic toggle="yes">P</italic> &gt; 0.05 (<italic toggle="yes">Figure</italic> <xref rid="fig3" ref-type="fig"><italic toggle="yes">3</italic></xref><italic toggle="yes">C</italic>). There was no interaction effect of treatment group and CKD subgroup (<italic toggle="yes">P</italic> = 0.724). Patients with severe renal impairment (≥30 and &lt;45 mL/min and ≥10 and &lt;30 mL/min) showed HRs of 0.82 and 0.97, respectively (<italic toggle="yes">P</italic> &gt; 0.05 for both groups).</p>
              </sec>
              <sec id="sec3-4">
                <title>Change in creatinine</title>
                <p>Following dronedarone treatment, creatinine levels initially increased in all eGFR subgroups but appeared to plateau after the first measurement (performed at Week 1) (<italic toggle="yes">Figure</italic> <xref rid="fig4" ref-type="fig"><italic toggle="yes">4</italic></xref>). In the more renally impaired subgroups, values returned close to baseline at later time points.</p>
                <fig position="float" id="fig4">
                  <label>Figure 4</label>
                  <caption>
                    <p>Percentage change from baseline in creatinine by estimated glomerular filtration rate category, with study time displayed on the <italic toggle="yes">x</italic>-axis.</p>
                  </caption>
                  <graphic xlink:href="pvab090fig4" position="float"/>
                </fig>
              </sec>
              <sec id="sec3-5">
                <title>Safety</title>
                <p>There was a general trend towards more TEAEs, serious TEAEs, and TEAEs leading to discontinuation in patients with more impaired renal function (<italic toggle="yes">Table</italic> <xref rid="tbl2" ref-type="table"><italic toggle="yes">2</italic></xref>). Differences between the dronedarone and placebo groups were small with regard to TEAEs and serious TEAEs. TEAEs leading to treatment discontinuation were more frequent in the dronedarone vs. placebo arm and were more prevalent in patients with poor renal function (ranging from 10.3% to 21.4% for dronedarone and from 7.8% to 9.6% for placebo). TEAEs leading to treatment discontinuation were primarily of gastrointestinal origin in both groups (<italic toggle="yes">Table</italic> <xref rid="tbl2" ref-type="table"><italic toggle="yes">2</italic></xref>); these gastrointestinal TEAEs were mostly attributable to diarrhoea and nausea. Few patients in either treatment group reported QT prolongation as a serious TEAE leading to treatment discontinuation [placebo: one patient (0.04%); dronedarone: four patients (0.2%)].</p>
                <table-wrap position="float" id="tbl2">
                  <label>Table 2</label>
                  <caption>
                    <p>Summary of treatment-emergent adverse events by treatment and estimated glomerular filtration rate subgroup (≥60, ≥45 and &lt;60, and &lt;45 mL/min)</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <thead>
                      <tr>
                        <th rowspan="1" colspan="1"/>
                        <th align="center" colspan="2" rowspan="1">eGFR ≥60 mL/min</th>
                        <th align="center" colspan="2" rowspan="1">eGFR ≥45 and &lt;60 mL/min</th>
                        <th align="center" colspan="2" rowspan="1">eGFR &lt;45 mL/min</th>
                      </tr>
                      <tr>
                        <th align="left" rowspan="1" colspan="1"><italic toggle="yes">n</italic> (%)</th>
                        <th align="left" rowspan="1" colspan="1">Placebo (<italic toggle="yes">n</italic> = 1301)</th>
                        <th align="left" rowspan="1" colspan="1">Dronedarone (<italic toggle="yes">n</italic> = 1320)</th>
                        <th align="left" rowspan="1" colspan="1">Placebo (<italic toggle="yes">n</italic> = 683)</th>
                        <th align="left" rowspan="1" colspan="1">Dronedarone (<italic toggle="yes">n</italic> = 649)</th>
                        <th align="left" rowspan="1" colspan="1">Placebo (<italic toggle="yes">n</italic> = 322)</th>
                        <th align="left" rowspan="1" colspan="1">Dronedarone (<italic toggle="yes">n</italic> = 313)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td rowspan="1" colspan="1">Any TEAE</td>
                        <td rowspan="1" colspan="1">886 (68.1)</td>
                        <td rowspan="1" colspan="1">921 (69.8)</td>
                        <td rowspan="1" colspan="1">479 (70.1)</td>
                        <td rowspan="1" colspan="1">478 (73.7)</td>
                        <td rowspan="1" colspan="1">233 (72.4)</td>
                        <td rowspan="1" colspan="1">243 (77.6)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Any serious TEAE</td>
                        <td rowspan="1" colspan="1">267 (20.5)</td>
                        <td rowspan="1" colspan="1">243 (18.4)</td>
                        <td rowspan="1" colspan="1">137 (20.1)</td>
                        <td rowspan="1" colspan="1">132 (20.3)</td>
                        <td rowspan="1" colspan="1">84 (26.1)</td>
                        <td rowspan="1" colspan="1">77 (24.6)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Any TEAE leading to discontinuation</td>
                        <td rowspan="1" colspan="1">102 (7.8)</td>
                        <td rowspan="1" colspan="1">136 (10.3)</td>
                        <td rowspan="1" colspan="1">55 (8.1)</td>
                        <td rowspan="1" colspan="1">90 (13.9)</td>
                        <td rowspan="1" colspan="1">31 (9.6)</td>
                        <td rowspan="1" colspan="1">67 (21.4)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Cardiac disorders</td>
                        <td rowspan="1" colspan="1">14 (1.1)</td>
                        <td rowspan="1" colspan="1">21 (1.6)</td>
                        <td rowspan="1" colspan="1">7 (1.0)</td>
                        <td rowspan="1" colspan="1">12 (1.8)</td>
                        <td rowspan="1" colspan="1">8 (2.5)</td>
                        <td rowspan="1" colspan="1">11 (3.5)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Gastrointestinal disorders</td>
                        <td rowspan="1" colspan="1">46 (3.5)</td>
                        <td rowspan="1" colspan="1">67 (5.1)</td>
                        <td rowspan="1" colspan="1">15 (2.2)</td>
                        <td rowspan="1" colspan="1">35 (5.4)</td>
                        <td rowspan="1" colspan="1">11 (3.4)</td>
                        <td rowspan="1" colspan="1">24 (7.7)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">General disorders and administration site conditions</td>
                        <td rowspan="1" colspan="1">28 (2.2)</td>
                        <td rowspan="1" colspan="1">28 (2.1)</td>
                        <td rowspan="1" colspan="1">14 (2.0)</td>
                        <td rowspan="1" colspan="1">16 (2.5)</td>
                        <td rowspan="1" colspan="1">8 (2.5)</td>
                        <td rowspan="1" colspan="1">18 (5.8)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Infections and infestations</td>
                        <td rowspan="1" colspan="1">19 (1.5)</td>
                        <td rowspan="1" colspan="1">23 (1.7)</td>
                        <td rowspan="1" colspan="1">9 (1.3)</td>
                        <td rowspan="1" colspan="1">17 (2.6)</td>
                        <td rowspan="1" colspan="1">9 (2.8)</td>
                        <td rowspan="1" colspan="1">10 (3.2)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Investigations</td>
                        <td rowspan="1" colspan="1">15 (1.2)</td>
                        <td rowspan="1" colspan="1">36 (2.7)</td>
                        <td rowspan="1" colspan="1">9 (1.3)</td>
                        <td rowspan="1" colspan="1">32 (4.9)</td>
                        <td rowspan="1" colspan="1">5 (1.6)</td>
                        <td rowspan="1" colspan="1">23 (7.3)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Metabolism and nutrition disorders</td>
                        <td rowspan="1" colspan="1">9 (0.7)</td>
                        <td rowspan="1" colspan="1">15 (1.1)</td>
                        <td rowspan="1" colspan="1">5 (0.7)</td>
                        <td rowspan="1" colspan="1">7 (1.1)</td>
                        <td rowspan="1" colspan="1">3 (0.9)</td>
                        <td rowspan="1" colspan="1">13 (4.2)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Musculoskeletal and connective tissue disorders</td>
                        <td rowspan="1" colspan="1">18 (1.4)</td>
                        <td rowspan="1" colspan="1">26 (2.0)</td>
                        <td rowspan="1" colspan="1">9 (1.3)</td>
                        <td rowspan="1" colspan="1">10 (1.5)</td>
                        <td rowspan="1" colspan="1">7 (2.2)</td>
                        <td rowspan="1" colspan="1">7 (2.2)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Nervous system disorders</td>
                        <td rowspan="1" colspan="1">25 (1.9)</td>
                        <td rowspan="1" colspan="1">33 (2.5)</td>
                        <td rowspan="1" colspan="1">9 (1.3)</td>
                        <td rowspan="1" colspan="1">14 (2.2)</td>
                        <td rowspan="1" colspan="1">9 (2.8)</td>
                        <td rowspan="1" colspan="1">10 (3.2)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Psychiatric disorders</td>
                        <td rowspan="1" colspan="1">7 (0.5)</td>
                        <td rowspan="1" colspan="1">15 (1.1)</td>
                        <td rowspan="1" colspan="1">5 (0.7)</td>
                        <td rowspan="1" colspan="1">3 (0.5)</td>
                        <td rowspan="1" colspan="1">8 (2.5)</td>
                        <td rowspan="1" colspan="1">2 (0.6)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Renal and urinary disorders</td>
                        <td rowspan="1" colspan="1">5 (0.4)</td>
                        <td rowspan="1" colspan="1">6 (0.5)</td>
                        <td rowspan="1" colspan="1">1 (0.1)</td>
                        <td rowspan="1" colspan="1">6 (0.9)</td>
                        <td rowspan="1" colspan="1">5 (1.6)</td>
                        <td rowspan="1" colspan="1">10 (3.2)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Respiratory, thoracic and mediastinal disorders</td>
                        <td rowspan="1" colspan="1">18 (1.4)</td>
                        <td rowspan="1" colspan="1">21 (1.6)</td>
                        <td rowspan="1" colspan="1">11 (1.6)</td>
                        <td rowspan="1" colspan="1">11 (1.7)</td>
                        <td rowspan="1" colspan="1">8 (2.5)</td>
                        <td rowspan="1" colspan="1">9 (2.9)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Skin and subcutaneous tissue disorders</td>
                        <td rowspan="1" colspan="1">17 (1.3)</td>
                        <td rowspan="1" colspan="1">27 (2.0)</td>
                        <td rowspan="1" colspan="1">4 (0.6)</td>
                        <td rowspan="1" colspan="1">11 (1.7)</td>
                        <td rowspan="1" colspan="1">6 (1.9)</td>
                        <td rowspan="1" colspan="1">9 (2.9)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="tb2fn1">
                      <p>Placebo group (overall): <italic toggle="yes">n</italic> = 2306; dronedarone group (overall): <italic toggle="yes">n</italic> = 2282. Treatment-emergent adverse event types leading to discontinuation in ≥2% of patients in any treatment group/estimated glomerular filtration rate subgroup are listed. eGFR, estimated glomerular filtration rate; TEAE, treatment-emergent adverse event.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>TEAEs in a subanalysis of patients with severe renal impairment are presented in the <xref rid="sup1" ref-type="supplementary-material">Supplementary material online, <italic toggle="yes">Table S1</italic></xref>. A higher proportion of patients receiving dronedarone reported TEAEs leading to treatment discontinuation compared with patients receiving placebo in all renal function groups; again, gastrointestinal TEAEs (primarily diarrhoea and nausea) leading to discontinuation were most commonly observed.</p>
              </sec>
              <sec id="sec3-6">
                <title>Modification of Diet in Renal Disease Study Group criteria and Cockcroft–Gault formula</title>
                <p>As a sensitivity analysis, outcomes were also analysed in eGFR strata classified according to the MDRD Study Group criteria and the Cockcroft–Gault formula, used in the original ATHENA analysis.<sup><xref rid="bib10" ref-type="bibr">10</xref></sup> The findings were unchanged and these data are not presented herein.</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="sec4">
              <title>Discussion</title>
              <p>This exploratory <italic toggle="yes">post hoc</italic> analysis of the ATHENA trial aimed to determine the efficacy and safety of dronedarone in relation to renal function. Dronedarone was associated with a lower incidence of first CV hospitalization or death from any cause vs. placebo across a wide spectrum of renal function, consistent with the outcomes of the primary ATHENA trial.<sup><xref rid="bib9" ref-type="bibr">9</xref></sup> These findings are supported by modelling of treatment by baseline eGFR as a continuous variable, rather than choosing the specific cut-off points dividing patients into subgroups. The failure to achieve statistical significance separately in the &lt;45 mL/min subgroup was most likely a reflection of the smaller population size resulting in reduced statistical power.</p>
              <p>Secondary endpoints, including CV hospitalization and first recurrence of AF/AFL, showed improved or similar outcomes with dronedarone vs. placebo, with the ≥60 mL/min and ≥45 and &lt;60 mL/min subgroups showing improvements that were statistically significant, but because of the <italic toggle="yes">post hoc</italic> nature of our analyses, further studies are needed to corroborate these findings. As expected, in ATHENA the risk for first CV hospitalization or death from any cause was higher in patients with renal impairment, in line with similar findings on the increased risk for all-cause and CV mortality with worsening renal impairment.<sup><xref rid="bib12" ref-type="bibr">12</xref></sup></p>
              <p>Dronedarone competes with creatinine for the renal tubular cation transport pathway, inhibiting tubular secretion of creatinine by ∼18% and subsequently increasing serum creatinine.<sup><xref rid="bib13" ref-type="bibr">13</xref></sup> Although this increase in serum creatinine was also described for dronedarone in the ANDROMEDA, EURIDIS-ADONIS, and PALLAS trials,<sup><xref rid="bib9" ref-type="bibr">9</xref></sup>,<sup><xref rid="bib14" ref-type="bibr">14–16</xref></sup> it does not represent a decrease in glomerular filtration rate (GFR).<sup><xref rid="bib13" ref-type="bibr">13</xref></sup> In this analysis, the increase in creatinine in the dronedarone groups was maintained until the end of the study in the ≥60 mL/min subgroup, but returned close to baseline in the subgroups with greater renal impairment.</p>
              <p>Although the study was not powered to detect differences between the treatment arms in subgroups based on renal function, the results did not show any signs of unfavourable individual outcomes with dronedarone across a wide spectrum of renal function. No significant difference in deaths from any cause was observed between dronedarone and placebo in any eGFR subgroup. Serious TEAEs and deaths did not differ notably between dronedarone and placebo in each group, although TEAEs leading to discontinuation were numerically higher in patients with an eGFR of &lt;45 mL/min receiving dronedarone vs. placebo. Another analysis of the ATHENA study has linked older age with a higher discontinuation rate;<sup><xref rid="bib17" ref-type="bibr">17</xref></sup> since older age was associated with worse renal function in the current analysis, this may explain the observed high rate of discontinuation in patients with severe renal impairment. CHA<sub>2</sub>DS<sub>2</sub>-VASc scores, a prognostic marker of increased risk for stroke or thromboembolic events and well recognized as a ‘frailty index’,<sup><xref rid="bib18" ref-type="bibr">18</xref></sup> were also higher in patients with more severe renal impairment, possibly reflecting a more fragile population of older age, with more comorbidities and medications with which possible drug–drug interactions and adverse effects are more common. While the higher medication burden in elderly vs. younger populations may increase the potential for adverse interaction, results from this analysis indicate that the rate of treatment discontinuation due to serious TEAEs involving bleeding/thrombotic events, QT prolongation, or heart failure was generally low, which may provide reassurance of the acceptable safety profile of dronedarone in this population.</p>
              <sec id="sec4-1">
                <title>Limitations</title>
                <p>This was a <italic toggle="yes">post hoc</italic> analysis of a prospective randomized controlled trial, and patients were not stratified according to renal function in the main trial. Splitting the overall trial population into eGFR categories meant that the number of participants in each subgroup was reduced compared with the overall study population in the original trial.<sup><xref rid="bib9" ref-type="bibr">9</xref></sup> This resulted in a loss of power, particularly in the most renally impaired &lt;45 mL/min subgroup [which constituted only 14% (<italic toggle="yes">n</italic> = 635) of included patients], although there was no interaction when studying eGFR as a continuous variable. The majority of patients had mild to moderate renal impairment, limiting the generalizability to patients with severe renal impairment. Finally, direct oral anticoagulants (DOACs) were not approved for atrial fibrillation at the time of the ATHENA study<sup><xref rid="bib19" ref-type="bibr">19</xref></sup> and so are not represented in the trial population; therefore, it is not possible to make any assessment of the safety/efficacy of dronedarone in conjunction with DOAC administration based on the current analysis.</p>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="sec5">
              <title>Conclusions</title>
              <p>Our findings demonstrate that dronedarone reduced first CV hospitalization or death from any cause in individuals with AF/AFL and additional risk factors across a wide range of renal function. Although dronedarone is an effective treatment in patients with structural heart disease and renal impairment compared with other AADs, which have limitations in their use or require dose reduction,<sup><xref rid="bib4" ref-type="bibr">4</xref></sup> further assessment of safety will be required in larger populations of patients with severe CKD.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <supplementary-material id="sup1" position="float" content-type="local-data">
                <label>pvab090_Supplemental_File</label>
                <media xlink:href="pvab090_supplemental_file.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="ack1">
              <title>Acknowledgements</title>
              <p>Editorial assistance was provided by Alex van der Wateren (PhD), of Fishawack Communications Ltd, and was funded by Sanofi. We thank Wanda Stipek, PharmD, BCPS (Sanofi), for coordination of the development, facilitating author discussions, and critical review of this manuscript.</p>
            </ack>
            <sec id="sec6">
              <sec id="sec6-1">
                <title>Funding</title>
                <p>Sanofi.</p>
              </sec>
            </sec>
            <sec id="sec7">
              <p><bold>Conflict of interest:</bold> M.V. reports receiving consulting fees and/or non-financial support from Abbott, Biotronik, Medtronic, Minimal lnvasive Technology, Pfizer, and Sanofi-Aventis, outside the submitted work. S.H.H. reports receiving consulting fees from Bayer Healthcare, BI, BMS, Boston Scientific, Daiichi Sankyo, Gilead, Johnson &amp; Johnson, Medtronic, Pfizer, Sanofi-Aventis, Servier, and Zoll and lecture fees from Bayer Healthcare, BI, BMS, Daiichi Sankyo, Pfizer, Sanofi-Aventis, and Medtronic. G.B.N. has no conflicts to declare. J.O. reports fees to his institution from AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Novartis, Pfizer, Roche Diagnostics, and Sanofi, outside the present work. G.Y.H.L. is a consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, and Daiichi Sankyo. No fees are received personally. H.C. is a consultant to Medtronic, Atricure, Abbott Medical, and Ablacon and reports honoraria from Medtronic and Ablacon. J.Z. reports receiving speaker fees from Boehringer Ingelheim, Bayer, and Novartis. K.C.U. reports no conflict of interest. M.W., U.L., and J.S. are employees of Sanofi and may hold shares and/or stock options in the company.</p>
            </sec>
            <ref-list id="ref1">
              <title>References</title>
              <ref id="bib1">
                <label>1.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Singh</surname><given-names>BN</given-names></string-name>, <string-name><surname>Singh</surname><given-names>SN</given-names></string-name>, <string-name><surname>Reda</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Tang</surname><given-names>XC</given-names></string-name>, <string-name><surname>Lopez</surname><given-names>B</given-names></string-name>, <string-name><surname>Harris</surname><given-names>CL</given-names></string-name>, <string-name><surname>Fletcher</surname><given-names>RD</given-names></string-name>, <string-name><surname>Sharma</surname><given-names>SC</given-names></string-name>, <string-name><surname>Atwood</surname><given-names>JE</given-names></string-name>, <string-name><surname>Jacobson</surname><given-names>AK</given-names></string-name>, <string-name><surname>Lewis</surname><given-names>HD</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Raisch</surname><given-names>DW</given-names></string-name>, <string-name><surname>Ezekowitz</surname><given-names>MD</given-names></string-name></person-group>. <article-title>Sotalol Amiodarone Atrial Fibrillation Efficacy Trial I. Amiodarone versus sotalol for atrial fibrillation</article-title>. <source>N Engl J Med</source><year>2005</year>;<volume>352</volume>:<fpage>1861</fpage>–<lpage>1872</lpage>.<pub-id pub-id-type="pmid">15872201</pub-id></mixed-citation>
              </ref>
              <ref id="bib2">
                <label>2.</label>
                <mixed-citation publication-type="journal"><comment>The National Institute for Health and Care Excellence (NICE)</comment>. <comment><ext-link xlink:href="https://www.nice.org.uk/guidance/cg180" ext-link-type="uri">https://www.nice.org.uk/guidance/cg180</ext-link> (November 2021)</comment>.</mixed-citation>
              </ref>
              <ref id="bib3">
                <label>3.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kirchhof</surname><given-names>P</given-names></string-name>, <string-name><surname>Camm</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Goette</surname><given-names>A</given-names></string-name>, <string-name><surname>Brandes</surname><given-names>A</given-names></string-name>, <string-name><surname>Eckardt</surname><given-names>L</given-names></string-name>, <string-name><surname>Elvan</surname><given-names>A</given-names></string-name>, <string-name><surname>Fetsch</surname><given-names>T</given-names></string-name>, <string-name><surname>van Gelder</surname><given-names>IC</given-names></string-name>, <string-name><surname>Haase</surname><given-names>D</given-names></string-name>, <string-name><surname>Haegeli</surname><given-names>LM</given-names></string-name>, <string-name><surname>Hamann</surname><given-names>F</given-names></string-name>, <string-name><surname>Heidbüchel</surname><given-names>H</given-names></string-name>, <string-name><surname>Hindricks</surname><given-names>G</given-names></string-name>, <string-name><surname>Kautzner</surname><given-names>J</given-names></string-name>, <string-name><surname>Kuck</surname><given-names>K-H</given-names></string-name>, <string-name><surname>Mont</surname><given-names>L</given-names></string-name>, <string-name><surname>Ng</surname><given-names>GA</given-names></string-name>, <string-name><surname>Rekosz</surname><given-names>J</given-names></string-name>, <string-name><surname>Schoen</surname><given-names>N</given-names></string-name>, <string-name><surname>Schotten</surname><given-names>U</given-names></string-name>, <string-name><surname>Suling</surname><given-names>A</given-names></string-name>, <string-name><surname>Taggeselle</surname><given-names>J</given-names></string-name>, <string-name><surname>Themistoclakis</surname><given-names>S</given-names></string-name>, <string-name><surname>Vettorazzi</surname><given-names>E</given-names></string-name>, <string-name><surname>Vardas</surname><given-names>P</given-names></string-name>, <string-name><surname>Wegscheider</surname><given-names>K</given-names></string-name>, <string-name><surname>Willems</surname><given-names>S</given-names></string-name>, <string-name><surname>Crijns</surname><given-names>HJGM</given-names></string-name>, <string-name><surname>Breithardt</surname><given-names>G</given-names></string-name></person-group>. <article-title>Early rhythm-control therapy in patients with atrial fibrillation</article-title>. <source>N Engl J Med</source><year>2020</year>;<volume>383</volume>:<fpage>1305</fpage>–<lpage>1316</lpage>.<pub-id pub-id-type="pmid">32865375</pub-id></mixed-citation>
              </ref>
              <ref id="bib4">
                <label>4.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Turakhia</surname><given-names>MP</given-names></string-name>, <string-name><surname>Blankestijn</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Carrero</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Clase</surname><given-names>CM</given-names></string-name>, <string-name><surname>Deo</surname><given-names>R</given-names></string-name>, <string-name><surname>Herzog</surname><given-names>CA</given-names></string-name>, <string-name><surname>Kasner</surname><given-names>SE</given-names></string-name>, <string-name><surname>Passman</surname><given-names>RS</given-names></string-name>, <string-name><surname>Pecoits-Filho</surname><given-names>R</given-names></string-name>, <string-name><surname>Reinecke</surname><given-names>H</given-names></string-name>, <string-name><surname>Shroff</surname><given-names>GR</given-names></string-name>, <string-name><surname>Zareba</surname><given-names>W</given-names></string-name>, <string-name><surname>Cheung</surname><given-names>M</given-names></string-name>, <string-name><surname>Wheeler</surname><given-names>DC</given-names></string-name>, <string-name><surname>Winkelmayer</surname><given-names>WC</given-names></string-name>, <string-name><surname>Wanner</surname><given-names>C</given-names></string-name>, <string-name><surname>Conference</surname><given-names>Participants</given-names></string-name></person-group>. <article-title>Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference</article-title>. <source>Eur Heart J</source><year>2018</year>;<volume>39</volume>:<fpage>2314</fpage>–<lpage>2325</lpage>.<pub-id pub-id-type="pmid">29522134</pub-id></mixed-citation>
              </ref>
              <ref id="bib5">
                <label>5.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Goto</surname><given-names>S</given-names></string-name>, <string-name><surname>Angchaisuksiri</surname><given-names>P</given-names></string-name>, <string-name><surname>Bassand</surname><given-names>JP</given-names></string-name>, <string-name><surname>Camm</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Dominguez</surname><given-names>H</given-names></string-name>, <string-name><surname>Illingworth</surname><given-names>L</given-names></string-name>, <string-name><surname>Gibbs</surname><given-names>H</given-names></string-name>, <string-name><surname>Goldhaber</surname><given-names>SZ</given-names></string-name>, <string-name><surname>Goto</surname><given-names>S</given-names></string-name>, <string-name><surname>Jing</surname><given-names>ZC</given-names></string-name>, <string-name><surname>Haas</surname><given-names>S</given-names></string-name>, <string-name><surname>Kayani</surname><given-names>G</given-names></string-name>, <string-name><surname>Koretsune</surname><given-names>Y</given-names></string-name>, <string-name><surname>Lim</surname><given-names>TW</given-names></string-name>, <string-name><surname>Oh</surname><given-names>S</given-names></string-name>, <string-name><surname>Sawhney</surname><given-names>JPS</given-names></string-name>, <string-name><surname>Turpie</surname><given-names>AGG</given-names></string-name>, <string-name><surname>van Eickels</surname><given-names>M</given-names></string-name>, <string-name><surname>Verheugt</surname><given-names>FWA</given-names></string-name>, <string-name><surname>Kakkar</surname><given-names>AK</given-names></string-name></person-group>, <person-group person-group-type="editor"><collab> GARFIELD‐AF Investigators</collab></person-group>. <article-title>Management and 1-year outcomes of patients with newly diagnosed atrial fibrillation and chronic kidney disease: results from the prospective GARFIELD-AF registry</article-title>. <source>J Am Heart Assoc</source><year>2019</year>;<volume>8</volume>:<fpage>e010510</fpage>.<pub-id pub-id-type="pmid">30717616</pub-id></mixed-citation>
              </ref>
              <ref id="bib6">
                <label>6.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lea-Henry</surname><given-names>TN</given-names></string-name>, <string-name><surname>Carland</surname><given-names>JE</given-names></string-name>, <string-name><surname>Stocker</surname><given-names>SL</given-names></string-name>, <string-name><surname>Sevastos</surname><given-names>J</given-names></string-name>, <string-name><surname>Roberts</surname><given-names>DM</given-names></string-name></person-group>. <article-title>Clinical pharmacokinetics in kidney disease: fundamental principles</article-title>. <source>Clin J Am Soc Nephrol</source><year>2018</year>;<volume>13</volume>:<fpage>1085</fpage>–<lpage>1095</lpage>.<pub-id pub-id-type="pmid">29934432</pub-id></mixed-citation>
              </ref>
              <ref id="bib7">
                <label>7.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jonsson</surname><given-names>KM</given-names></string-name>, <string-name><surname>Wieloch</surname><given-names>M</given-names></string-name>, <string-name><surname>Sterner</surname><given-names>G</given-names></string-name>, <string-name><surname>Nyman</surname><given-names>U</given-names></string-name>, <string-name><surname>Elmstahl</surname><given-names>S</given-names></string-name>, <string-name><surname>Engstrom</surname><given-names>G</given-names></string-name>, <string-name><surname>Svensson</surname><given-names>PJ</given-names></string-name></person-group>. <article-title>Glomerular filtration rate in patients with atrial fibrillation on warfarin treatment: a subgroup analysis from the AURICULA registry in Sweden</article-title>. <source>Thromb Res</source><year>2011</year>;<volume>128</volume>:<fpage>341</fpage>–<lpage>345</lpage>.<pub-id pub-id-type="pmid">21620441</pub-id></mixed-citation>
              </ref>
              <ref id="bib8">
                <label>8.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Koziel</surname><given-names>M</given-names></string-name>, <string-name><surname>Simovic</surname><given-names>S</given-names></string-name>, <string-name><surname>Pavlovic</surname><given-names>N</given-names></string-name>, <string-name><surname>Nedeljkovic</surname><given-names>M</given-names></string-name>, <string-name><surname>Kocijancic</surname><given-names>A</given-names></string-name>, <string-name><surname>Paparisto</surname><given-names>V</given-names></string-name>, <string-name><surname>Music</surname><given-names>L</given-names></string-name>, <string-name><surname>Trendafilova</surname><given-names>E</given-names></string-name>, <string-name><surname>Dan</surname><given-names>AR</given-names></string-name>, <string-name><surname>Manola</surname><given-names>S</given-names></string-name>, <string-name><surname>Kusljugic</surname><given-names>Z</given-names></string-name>, <string-name><surname>Dan</surname><given-names>GA</given-names></string-name>, <string-name><surname>Lip</surname><given-names>GYH</given-names></string-name>, <string-name><surname>Potpara</surname><given-names>TS</given-names></string-name></person-group>, <person-group person-group-type="editor"><collab> Balkan-AF Investigators</collab></person-group>. <article-title>Treatment implications of renal disease in patients with atrial fibrillation: the BALKAN-AF survey</article-title>. <source>J Arrhythm</source><year>2020</year>;<volume>36</volume>:<fpage>863</fpage>–<lpage>873</lpage>.<pub-id pub-id-type="pmid">33024464</pub-id></mixed-citation>
              </ref>
              <ref id="bib9">
                <label>9.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hohnloser</surname><given-names>SH</given-names></string-name>, <string-name><surname>Crijns</surname><given-names>HJ</given-names></string-name>, <string-name><surname>van Eickels</surname><given-names>M</given-names></string-name>, <string-name><surname>Gaudin</surname><given-names>C</given-names></string-name>, <string-name><surname>Page</surname><given-names>RL</given-names></string-name>, <string-name><surname>Torp-Pedersen</surname><given-names>C</given-names></string-name>, <string-name><surname>Connolly</surname><given-names>SJ</given-names></string-name></person-group>, <person-group person-group-type="editor"><collab> ATHENA Investigators</collab></person-group>. <article-title>Effect of dronedarone on cardiovascular events in atrial fibrillation</article-title>. <source>N Engl J Med</source><year>2009</year>;<volume>360</volume>:<fpage>668</fpage>–<lpage>678</lpage>.<pub-id pub-id-type="pmid">19213680</pub-id></mixed-citation>
              </ref>
              <ref id="bib10">
                <label>10.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hohnloser</surname><given-names>SH</given-names></string-name>, <string-name><surname>Connolly</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Crijns</surname><given-names>HJ</given-names></string-name>, <string-name><surname>Page</surname><given-names>RL</given-names></string-name>, <string-name><surname>Seiz</surname><given-names>W</given-names></string-name>, <string-name><surname>Torp-Petersen</surname><given-names>C</given-names></string-name></person-group>. <article-title>Rationale and design of ATHENA: A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter</article-title>. <source>J Cardiovasc Electrophysiol</source><year>2008</year>;<volume>19</volume>:<fpage>69</fpage>–<lpage>73</lpage>.<pub-id pub-id-type="pmid">18031520</pub-id></mixed-citation>
              </ref>
              <ref id="bib11">
                <label>11.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Levey</surname><given-names>AS</given-names></string-name>, <string-name><surname>Inker</surname><given-names>LA</given-names></string-name>, <string-name><surname>Coresh</surname><given-names>J</given-names></string-name></person-group>. <article-title>GFR estimation: from physiology to public health</article-title>. <source>Am J Kidney Dis</source><year>2014</year>;<volume>63</volume>:<fpage>820</fpage>–<lpage>834</lpage>.<pub-id pub-id-type="pmid">24485147</pub-id></mixed-citation>
              </ref>
              <ref id="bib12">
                <label>12.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tonelli</surname><given-names>M</given-names></string-name>, <string-name><surname>Wiebe</surname><given-names>N</given-names></string-name>, <string-name><surname>Culleton</surname><given-names>B</given-names></string-name>, <string-name><surname>House</surname><given-names>A</given-names></string-name>, <string-name><surname>Rabbat</surname><given-names>C</given-names></string-name>, <string-name><surname>Fok</surname><given-names>M</given-names></string-name>, <string-name><surname>McAlister</surname><given-names>F</given-names></string-name>, <string-name><surname>Garg</surname><given-names>AX</given-names></string-name></person-group>. <article-title>Chronic kidney disease and mortality risk: a systematic review</article-title>. <source>J Am Soc Nephrol</source><year>2006</year>;<volume>17</volume>:<fpage>2034</fpage>–<lpage>2047</lpage>.<pub-id pub-id-type="pmid">16738019</pub-id></mixed-citation>
              </ref>
              <ref id="bib13">
                <label>13.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tschuppert</surname><given-names>Y</given-names></string-name>, <string-name><surname>Buclin</surname><given-names>T</given-names></string-name>, <string-name><surname>Rothuizen</surname><given-names>LE</given-names></string-name>, <string-name><surname>Decosterd</surname><given-names>LA</given-names></string-name>, <string-name><surname>Galleyrand</surname><given-names>J</given-names></string-name>, <string-name><surname>Gaud</surname><given-names>C</given-names></string-name>, <string-name><surname>Biollaz</surname><given-names>J</given-names></string-name></person-group>. <article-title>Effect of dronedarone on renal function in healthy subjects</article-title>. <source>Br J Clin Pharmacol</source><year>2007</year>;<volume>64</volume>:<fpage>785</fpage>–<lpage>791</lpage>.<pub-id pub-id-type="pmid">17662087</pub-id></mixed-citation>
              </ref>
              <ref id="bib14">
                <label>14.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Connolly</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Camm</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Halperin</surname><given-names>JL</given-names></string-name>, <string-name><surname>Joyner</surname><given-names>C</given-names></string-name>, <string-name><surname>Alings</surname><given-names>M</given-names></string-name>, <string-name><surname>Amerena</surname><given-names>J</given-names></string-name>, <string-name><surname>Atar</surname><given-names>D</given-names></string-name>, <string-name><surname>Avezum</surname><given-names>A</given-names></string-name>, <string-name><surname>Blomstrom</surname><given-names>P</given-names></string-name>, <string-name><surname>Borggrefe</surname><given-names>M</given-names></string-name>, <string-name><surname>Budaj</surname><given-names>A</given-names></string-name>, <string-name><surname>Chen</surname><given-names>SA</given-names></string-name>, <string-name><surname>Ching</surname><given-names>CK</given-names></string-name>, <string-name><surname>Commerford</surname><given-names>P</given-names></string-name>, <string-name><surname>Dans</surname><given-names>A</given-names></string-name>, <string-name><surname>Davy</surname><given-names>JM</given-names></string-name>, <string-name><surname>Delacretaz</surname><given-names>E</given-names></string-name>, <string-name><surname>Di Pasquale</surname><given-names>G</given-names></string-name>, <string-name><surname>Diaz</surname><given-names>R</given-names></string-name>, <string-name><surname>Dorian</surname><given-names>P</given-names></string-name>, <string-name><surname>Flaker</surname><given-names>G</given-names></string-name>, <string-name><surname>Golitsyn</surname><given-names>S</given-names></string-name>, <string-name><surname>Gonzalez-Hermosillo</surname><given-names>A</given-names></string-name>, <string-name><surname>Granger</surname><given-names>CB</given-names></string-name>, <string-name><surname>Heidbuchel</surname><given-names>H</given-names></string-name>, <string-name><surname>Kautzner</surname><given-names>J</given-names></string-name>, <string-name><surname>Kim</surname><given-names>JS</given-names></string-name>, <string-name><surname>Lanas</surname><given-names>F</given-names></string-name>, <string-name><surname>Lewis</surname><given-names>BS</given-names></string-name>, <string-name><surname>Merino</surname><given-names>JL</given-names></string-name>, <string-name><surname>Morillo</surname><given-names>C</given-names></string-name>, <string-name><surname>Murin</surname><given-names>J</given-names></string-name>, <string-name><surname>Narasimhan</surname><given-names>C</given-names></string-name>, <string-name><surname>Paolasso</surname><given-names>E</given-names></string-name>, <string-name><surname>Parkhomenko</surname><given-names>A</given-names></string-name>, <string-name><surname>Peters</surname><given-names>NS</given-names></string-name>, <string-name><surname>Sim</surname><given-names>KH</given-names></string-name>, <string-name><surname>Stiles</surname><given-names>MK</given-names></string-name>, <string-name><surname>Tanomsup</surname><given-names>S</given-names></string-name>, <string-name><surname>Toivonen</surname><given-names>L</given-names></string-name>, <string-name><surname>Tomcsanyi</surname><given-names>J</given-names></string-name>, <string-name><surname>Torp-Pedersen</surname><given-names>C</given-names></string-name>, <string-name><surname>Tse</surname><given-names>HF</given-names></string-name>, <string-name><surname>Vardas</surname><given-names>P</given-names></string-name>, <string-name><surname>Vinereanu</surname><given-names>D</given-names></string-name>, <string-name><surname>Xavier</surname><given-names>D</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>J</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>JR</given-names></string-name>, <string-name><surname>Baret-Cormel</surname><given-names>L</given-names></string-name>, <string-name><surname>Weinling</surname><given-names>E</given-names></string-name>, <string-name><surname>Staiger</surname><given-names>C</given-names></string-name>, <string-name><surname>Yusuf</surname><given-names>S</given-names></string-name>, <string-name><surname>Chrolavicius</surname><given-names>S</given-names></string-name>, <string-name><surname>Afzal</surname><given-names>R</given-names></string-name>, <string-name><surname>Hohnloser</surname><given-names>SH</given-names></string-name></person-group>, <person-group person-group-type="editor"><collab> PALLAS Investigators</collab></person-group>. <article-title>Dronedarone in high-risk permanent atrial fibrillation</article-title>. <source>N Engl J Med</source><year>2011</year>;<volume>365</volume>:<fpage>2268</fpage>–<lpage>2276</lpage>.<pub-id pub-id-type="pmid">22082198</pub-id></mixed-citation>
              </ref>
              <ref id="bib15">
                <label>15.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kober</surname><given-names>L</given-names></string-name>, <string-name><surname>Torp-Pedersen</surname><given-names>C</given-names></string-name>, <string-name><surname>McMurray</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Gotzsche</surname><given-names>O</given-names></string-name>, <string-name><surname>Levy</surname><given-names>S</given-names></string-name>, <string-name><surname>Crijns</surname><given-names>H</given-names></string-name>, <string-name><surname>Amlie</surname><given-names>J</given-names></string-name>, <string-name><surname>Carlsen</surname><given-names>J</given-names></string-name></person-group>, <person-group person-group-type="editor"><collab> Dronedarone Study Group</collab></person-group>. <article-title>Increased mortality after dronedarone therapy for severe heart failure</article-title>. <source>N Engl J Med</source><year>2008</year>;<volume>358</volume>:<fpage>2678</fpage>–<lpage>2687</lpage>.<pub-id pub-id-type="pmid">18565860</pub-id></mixed-citation>
              </ref>
              <ref id="bib16">
                <label>16.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Singh</surname><given-names>BN</given-names></string-name>, <string-name><surname>Connolly</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Crijns</surname><given-names>HJ</given-names></string-name>, <string-name><surname>Roy</surname><given-names>D</given-names></string-name>, <string-name><surname>Kowey</surname><given-names>PR</given-names></string-name>, <string-name><surname>Capucci</surname><given-names>A</given-names></string-name>, <string-name><surname>Radzik</surname><given-names>D</given-names></string-name>, <string-name><surname>Aliot</surname><given-names>EM</given-names></string-name>, <string-name><surname>Hohnloser</surname><given-names>SH</given-names></string-name>, <string-name name-style="given-only"><given-names>Euridis</given-names></string-name><collab> ADONIS Investigators</collab></person-group>. <article-title>Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter</article-title>. <source>N Engl J Med</source><year>2007</year>;<volume>357</volume>:<fpage>987</fpage>–<lpage>999</lpage>.<pub-id pub-id-type="pmid">17804843</pub-id></mixed-citation>
              </ref>
              <ref id="bib17">
                <label>17.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Curtis</surname><given-names>AB</given-names></string-name>, <string-name><surname>Zeitler</surname><given-names>EP</given-names></string-name>, <string-name><surname>Malik</surname><given-names>A</given-names></string-name>, <string-name><surname>Bogard</surname><given-names>A</given-names></string-name>, <string-name><surname>Bhattacharyya</surname><given-names>N</given-names></string-name>, <string-name><surname>Stewart</surname><given-names>J</given-names></string-name>, <string-name><surname>Hohnloser</surname><given-names>SH</given-names></string-name></person-group>. <article-title>Efficacy and safety of dronedarone across age and sex subgroups: a <italic toggle="yes">post hoc</italic> analysis of the ATHENA study among patients with non-permanent atrial fibrillation/flutter</article-title>. <source>Europace</source><year>2021</year>;<fpage>1</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">33230529</pub-id></mixed-citation>
              </ref>
              <ref id="bib18">
                <label>18.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Philippart</surname><given-names>R</given-names></string-name>, <string-name><surname>Brunet-Bernard</surname><given-names>A</given-names></string-name>, <string-name><surname>Clementy</surname><given-names>N</given-names></string-name>, <string-name><surname>Bourguignon</surname><given-names>T</given-names></string-name>, <string-name><surname>Mirza</surname><given-names>A</given-names></string-name>, <string-name><surname>Babuty</surname><given-names>D</given-names></string-name>, <string-name><surname>Angoulvant</surname><given-names>D</given-names></string-name>, <string-name><surname>Lip</surname><given-names>GY</given-names></string-name>, <string-name><surname>Fauchier</surname><given-names>L</given-names></string-name></person-group>. <article-title>Prognostic value of CHA<sub>2</sub>DS<sub>2</sub>-VASc score in patients with ‘non-valvular atrial fibrillation’ and valvular heart disease: the Loire Valley Atrial Fibrillation Project</article-title>. <source>Eur Heart J</source><year>2015</year>;<volume>36</volume>:<fpage>1822</fpage>–<lpage>1830</lpage>.</mixed-citation>
              </ref>
              <ref id="bib19">
                <label>19.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>A</given-names></string-name>, <string-name><surname>Stecker</surname><given-names>E</given-names></string-name>, <string-name><surname>AW</surname><given-names>B</given-names></string-name></person-group>. <article-title>Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges</article-title>. <source>J Am Heart Assoc</source><year>2020</year>;<volume>9</volume>:<fpage>e017559</fpage>.<pub-id pub-id-type="pmid">32538234</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
